Outcomes
The primary efficacy endpoint was the treatment outcome (success or failure) in patients with late-stage HAT assessed 18 months after acoziborole treatment (per protocol population), based on modified WHO criteria.A complementary post-hoc analysis of the 18-month success rate was done to compare acoziborole (the primary analysis) with NECT (using data from Priotto and colleagues